<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00694473</url>
  </required_header>
  <id_info>
    <org_study_id>2007P-002178</org_study_id>
    <nct_id>NCT00694473</nct_id>
  </id_info>
  <brief_title>Continuous Glucose Monitoring With a Subcutaneous Sensor During Critical Illness and Surgery</brief_title>
  <official_title>Continuous Glucose Monitoring With a Subcutaneous Sensor During Critical Illness and Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott Diabetes Care</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hypothesize that measurements of interstitial fluid (ISF) glucose by the FreeStyle
      Navigator (Abbot Diabetes Care), a continuous glucose monitoring system, will correlate with
      blood glucose (BG) values in surgical and ICU patients with a clinically useful degree of
      accuracy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Critically ill patients treated with intensive insulin therapy will be monitored for up to 72
      hours with the Freestyle Navigator continuous glucose monitor. The device display will be
      disabled so that continuous glucose monitoring results will not be available to care givers,
      although low (&lt;60 mg/dL) and high (&gt;250 mg/dL) threshold audio alarms will be enabled. Blood
      glucose monitoring will be performed according to the usual practice for patients treated
      with intensive insulin therapy in each intensive care unit, except that additional blood
      glucose measurements will be performed in response to Freestyle Navigator threshold alarm.
      All blood glucose management decisions will be made according to intensive insulin therapy
      protocol in each unit. Freestyle Navigator data will be downloaded from the device after each
      subject has completed the monitoring period. Blood glucose values obtained in the course of
      usual care, or in response to Freestyle Navigator threshold alarms, will be compared with
      time-matched Freestyle Navigator values to assess device accuracy and alarm sensitivity and
      specificity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity and Specificity of Navigator Threshold Alarms for Hypoglycemia (&lt;60 mg/dl).</measure>
    <time_frame>72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and Specificity of Navigator Threshold Alarms for Hyperglycemia (&gt;240 mg/dl).</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accuracy of Navigator CGM as Compared to Reference Blood Glucose Values</measure>
    <time_frame>72 hours</time_frame>
    <description>Mean Absolute Relative Difference (MARD) of Navigator CGM compared with reference blood glucose values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and Specificity of Navigator Projected Low Blood Sugar Alarm Criteria Calculated for Events Defined by a Low Reference BG Value (&lt; 60 mg/dL)</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and Specificity of Navigator Projected High Blood Sugar Alarm Criteria Calculated for Events Defined by a High Reference BG Value (&gt; 250 mg/dl)</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Readings in Different Blood Sugar Ranges as Shown by Point of Care Testing:</measure>
    <time_frame>72 hours</time_frame>
    <description>Percentage of readings in different blood sugar ranges as shown by point of care testing:
&lt; 60 mg/dl 61-120 mg/dl 121-180 mg/dl 181-240 lmg/dl &gt;240 mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Navigator CGM Accuracy by Category</measure>
    <time_frame>72 hours</time_frame>
    <description>Mean Absolute Relative Difference (MARD) between the Navigator CGM and reference blood glucose values by category (1, Neurosurgery; 2, Cardiac Surgery; 3, Hypotensive/Vasopressor; 4, Edema; 5, None of the Above)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>Freestyle Navigator</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continuous monitoring with the Freestyle Navigator for 72 hours or until discharge from the ICU</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Freestyle Navigator</intervention_name>
    <description>Continuous glucose monitoring with the Freestyle Navigator for 72 hours or until discharge from the ICU</description>
    <arm_group_label>Freestyle Navigator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients admitted to the general surgical ICU (SICU), medical ICU (MICU), cardiac
             surgery intensive care unit (CSICU), or neurological intensive care unit (NeuroICU),
             are being treated with IIT, and have an arterial line in place

          -  Patients scheduled for open cardiac surgery or craniotomy that have diabetes mellitus
             or will be given high dose glucocorticoids. All of these patient will have an arterial
             line placed at the time of surgery as a part of their usual care

        Exclusion Criteria:

          -  Age less than 18 years

          -  Enrollment in another clinical trial that modifies their glucose management (e.g.
             trial of modified IIT algorithm or modified glucose monitoring regimen)

        In order to obtain adequate representation of patients with physiological alterations that
        might decrease correspondence between blood and ISF glucose, we will recruit 50 subjects in
        each of five groups:

          1. Patients undergoing craniotomy who are either diabetic or will be given high dose
             corticosteroids

          2. Diabetic patients undergoing open cardiac surgery

          3. Patients admitted to one of the participating ICUs with an arterial line in place and
             receiving IIT who are vasopressor dependent, defined by continuous infusion of at
             least 60 mg/min phenylephrine, 5 mg/min norepinephrine, or 10 mg/kg/min of dopamine,
             or any combination of two agents for at least 90 continuous minutes in the last 8
             hours

          4. Patients admitted to one of the participating ICUs with an arterial line in place and
             receiving IIT with pitting peripheral or dependent edema, defined by the persistence
             of pitting to at least 5 mm depth for 5 seconds after pressure is applied to a
             dependent area of the trunk or two limbs.

          5. Critically ill patients admitted to one of the participating ICUs with an arterial
             line in place and receiving IIT who do not fall into groups 1-4.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven J. Russell, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2008</study_first_submitted>
  <study_first_submitted_qc>June 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2008</study_first_posted>
  <results_first_submitted>November 23, 2016</results_first_submitted>
  <results_first_submitted_qc>October 4, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 6, 2017</results_first_posted>
  <last_update_submitted>February 7, 2018</last_update_submitted>
  <last_update_submitted_qc>February 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Steven J. Russell, MD, PhD</investigator_full_name>
    <investigator_title>Assistant in Medicine</investigator_title>
  </responsible_party>
  <keyword>hyperglycemia</keyword>
  <keyword>hypoglycemia</keyword>
  <keyword>insulin</keyword>
  <keyword>critical illness</keyword>
  <keyword>intensive insulin therapy</keyword>
  <keyword>continuous glucose monitoring</keyword>
  <keyword>CGM</keyword>
  <keyword>interstitial fluid glucose</keyword>
  <keyword>intensive care unit</keyword>
  <keyword>Blood glucose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Freestyle Navigator</title>
          <description>Continuous monitoring with the Freestyle Navigator for 72 hours or until discharge from the ICU
Freestyle Navigator: Continuous glucose monitoring with the Freestyle Navigator for 72 hours or until discharge from the ICU</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="76">Aug 2008</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="69">Dec 2010</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>76 were enrolled, analysis was completed for 69</population>
      <group_list>
        <group group_id="B1">
          <title>Freestyle Navigator</title>
          <description>Continuous monitoring with the Freestyle Navigator for 72 hours or until discharge from the ICU
Freestyle Navigator: Continuous glucose monitoring with the Freestyle Navigator for 72 hours or until discharge from the ICU</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="69"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sensitivity and Specificity of Navigator Threshold Alarms for Hypoglycemia (&lt;60 mg/dl).</title>
        <time_frame>72 hours</time_frame>
        <population>This measure was not calculated as we did not have sufficient data to calculate sensitivity (not enough hypoglycemia) and discordant BG check times to calculate specificity.</population>
        <group_list>
          <group group_id="O1">
            <title>Freestyle Navigator</title>
            <description>Continuous monitoring with the Freestyle Navigator for 72 hours or until discharge from the ICU
Freestyle Navigator: Continuous glucose monitoring with the Freestyle Navigator for 72 hours or until discharge from the ICU</description>
          </group>
        </group_list>
        <measure>
          <title>Sensitivity and Specificity of Navigator Threshold Alarms for Hypoglycemia (&lt;60 mg/dl).</title>
          <population>This measure was not calculated as we did not have sufficient data to calculate sensitivity (not enough hypoglycemia) and discordant BG check times to calculate specificity.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sensitivity and Specificity of Navigator Threshold Alarms for Hyperglycemia (&gt;240 mg/dl).</title>
        <time_frame>72 hours</time_frame>
        <population>This measure was not calculated as we did not have sufficient data to calculate sensitivity and inappropriate BG check times to calculate specificity and few trends towards hyperglycemia</population>
        <group_list>
          <group group_id="O1">
            <title>Freestyle Navigator</title>
            <description>Continuous monitoring with the Freestyle Navigator for 72 hours or until discharge from the ICU
Freestyle Navigator: Continuous glucose monitoring with the Freestyle Navigator for 72 hours or until discharge from the ICU</description>
          </group>
        </group_list>
        <measure>
          <title>Sensitivity and Specificity of Navigator Threshold Alarms for Hyperglycemia (&gt;240 mg/dl).</title>
          <population>This measure was not calculated as we did not have sufficient data to calculate sensitivity and inappropriate BG check times to calculate specificity and few trends towards hyperglycemia</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Accuracy of Navigator CGM as Compared to Reference Blood Glucose Values</title>
        <description>Mean Absolute Relative Difference (MARD) of Navigator CGM compared with reference blood glucose values</description>
        <time_frame>72 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Freestyle Navigator</title>
            <description>Continuous monitoring with the Freestyle Navigator for 72 hours or until discharge from the ICU
Freestyle Navigator: Continuous glucose monitoring with the Freestyle Navigator for 72 hours or until discharge from the ICU</description>
          </group>
        </group_list>
        <measure>
          <title>Accuracy of Navigator CGM as Compared to Reference Blood Glucose Values</title>
          <description>Mean Absolute Relative Difference (MARD) of Navigator CGM compared with reference blood glucose values</description>
          <units>percent absolute relative difference</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" lower_limit="13.0" upper_limit="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sensitivity and Specificity of Navigator Projected Low Blood Sugar Alarm Criteria Calculated for Events Defined by a Low Reference BG Value (&lt; 60 mg/dL)</title>
        <time_frame>72 hours</time_frame>
        <population>This measure was not calculated as we did not have sufficient data to calculate sensitivity (not enough hypoglycemia) and discordant BG check times to calculate specificity.</population>
        <group_list>
          <group group_id="O1">
            <title>Freestyle Navigator</title>
            <description>Continuous monitoring with the Freestyle Navigator for 72 hours or until discharge from the ICU
Freestyle Navigator: Continuous glucose monitoring with the Freestyle Navigator for 72 hours or until discharge from the ICU</description>
          </group>
        </group_list>
        <measure>
          <title>Sensitivity and Specificity of Navigator Projected Low Blood Sugar Alarm Criteria Calculated for Events Defined by a Low Reference BG Value (&lt; 60 mg/dL)</title>
          <population>This measure was not calculated as we did not have sufficient data to calculate sensitivity (not enough hypoglycemia) and discordant BG check times to calculate specificity.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sensitivity and Specificity of Navigator Projected High Blood Sugar Alarm Criteria Calculated for Events Defined by a High Reference BG Value (&gt; 250 mg/dl)</title>
        <time_frame>72 hours</time_frame>
        <population>This measure was not calculated as we did not have sufficient data to calculate sensitivity and inappropriate BG check times to calculate specificity and few trends towards hyperglycemia</population>
        <group_list>
          <group group_id="O1">
            <title>Freestyle Navigator</title>
            <description>Continuous monitoring with the Freestyle Navigator for 72 hours or until discharge from the ICU
Freestyle Navigator: Continuous glucose monitoring with the Freestyle Navigator for 72 hours or until discharge from the ICU</description>
          </group>
        </group_list>
        <measure>
          <title>Sensitivity and Specificity of Navigator Projected High Blood Sugar Alarm Criteria Calculated for Events Defined by a High Reference BG Value (&gt; 250 mg/dl)</title>
          <population>This measure was not calculated as we did not have sufficient data to calculate sensitivity and inappropriate BG check times to calculate specificity and few trends towards hyperglycemia</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Readings in Different Blood Sugar Ranges as Shown by Point of Care Testing:</title>
        <description>Percentage of readings in different blood sugar ranges as shown by point of care testing:
&lt; 60 mg/dl 61-120 mg/dl 121-180 mg/dl 181-240 lmg/dl &gt;240 mg/dl</description>
        <time_frame>72 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Freestyle Navigator</title>
            <description>Continuous monitoring with the Freestyle Navigator for 72 hours or until discharge from the ICU
Freestyle Navigator: Continuous glucose monitoring with the Freestyle Navigator for 72 hours or until discharge from the ICU</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Readings in Different Blood Sugar Ranges as Shown by Point of Care Testing:</title>
          <description>Percentage of readings in different blood sugar ranges as shown by point of care testing:
&lt; 60 mg/dl 61-120 mg/dl 121-180 mg/dl 181-240 lmg/dl &gt;240 mg/dl</description>
          <units>percentage of readings</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;60mg/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>61-120mg/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>121-180mg/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>181-240mg/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;240mg/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Navigator CGM Accuracy by Category</title>
        <description>Mean Absolute Relative Difference (MARD) between the Navigator CGM and reference blood glucose values by category (1, Neurosurgery; 2, Cardiac Surgery; 3, Hypotensive/Vasopressor; 4, Edema; 5, None of the Above)</description>
        <time_frame>72 hours</time_frame>
        <population>MARD by category (1, Neurosurgery; 2, Cardiac Surgery; 3, Hypotensive/Vasopressor; 4, Edema; 5, None of the Above)</population>
        <group_list>
          <group group_id="O1">
            <title>Freestyle Navigator</title>
            <description>Continuous monitoring with the Freestyle Navigator for 72 hours or until discharge from the ICU
Freestyle Navigator: Continuous glucose monitoring with the Freestyle Navigator for 72 hours or until discharge from the ICU</description>
          </group>
        </group_list>
        <measure>
          <title>Navigator CGM Accuracy by Category</title>
          <description>Mean Absolute Relative Difference (MARD) between the Navigator CGM and reference blood glucose values by category (1, Neurosurgery; 2, Cardiac Surgery; 3, Hypotensive/Vasopressor; 4, Edema; 5, None of the Above)</description>
          <population>MARD by category (1, Neurosurgery; 2, Cardiac Surgery; 3, Hypotensive/Vasopressor; 4, Edema; 5, None of the Above)</population>
          <units>percent absolute relative difference</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Neurosurgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiac surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypotensive/vasopressor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8" spread="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Edema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>72 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Freestyle Navigator</title>
          <description>Continuous monitoring with the Freestyle Navigator for 72 hours or until discharge from the ICU
Freestyle Navigator: Continuous glucose monitoring with the Freestyle Navigator for 72 hours or until discharge from the ICU</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Culture proven bacteremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bleeding at Insertion Site</sub_title>
                <description>Bleeding at the insertion site of the subcutaneous sensor</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Analysis used recalibrated data from Abbot; possible bias. Time of A-line removal was not always documented; estimate of arterial vs. venous POC reference BGs is estimated.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Steven J Russell, M.D. PhD</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-726-8722</phone>
      <email>sjrussell@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

